Download Files:
Ridaforolimus
SKU
HY-50908-10 mg
Category Reference compound
Tags Anti-infection;Autophagy;PI3K/Akt/mTOR, Autophagy;Bacterial;mTOR, Cancer
$65 – $391
Products Details
Product Description
– Ridaforolimus (MK-8669) is a potent and selective mTOR inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells[1].
Web ID
– HY-50908
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C53H84NO14P
References
– [1]Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. Cell Metab. 2018 Jan 9;27(1):118-135.e8.|[2]Rivera VM, et al. Deforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011 Jun;10(6):1059-71.
CAS Number
– 572924-54-0
Molecular Weight
– 990.21
Compound Purity
– 98.81
SMILES
– O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@@H]4C[C@H]([C@H](OP(C)(C)=O)CC4)OC)C)=O)=O
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : ≥ 44 mg/mL
Target
– Autophagy;Bacterial;mTOR
Isoform
– mTORC1
Pathway
– Anti-infection;Autophagy;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.